Suzhou Ribo Life Science Co., Ltd. (HKG:6938)
Hong Kong · Delayed Price · Currency is HKD 70.05
-4.00 (-5.40%)
At close: Feb 13, 2026
Suzhou Ribo Life Science Company Description
Suzhou Ribo Life Science Co., Ltd. researches and develops small nucleic acid drugs for treating cardiovascular, metabolic, renal, liver, and other diseases.
It develops RBD4059 for treating thrombotic diseases; RBD5044 for treating hypertrigly ceridemia; RBD7022 for treating Hypercho lesterolemia; RBD1016 for treating CHB and CHD that are in Phase II clinical trials.
The company also develops RBD7007 and RBD2080 for treating renal diseases; and RBD1119 for treating thrombotic diseases, which are in Phase I clinical trials.
In addition, it develops SR122 for treating dyslipidemia; RBD3103 for treating renal diseases; and RBD8088 for treating glioma that are in preclinical trials.
The company was founded in 2007 and is based in Kunshan, China.
Suzhou Ribo Life Science Co., Ltd.
| Country | China |
| Founded | 2007 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 404 |
Contact Details
Address: No.168, Yuanfeng Road Kunshan, 215300 China | |
| Phone | 86 512 57017802 |
| Website | ribolia.com |
Stock Details
| Ticker Symbol | 6938 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| SIC Code | 2836 |